Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Bellevue Group AG

Bellevue Group AG increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 36.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 344,348 shares of the biotechnology company's stock after purchasing an additional 92,027 shares during the period. Bellevue Group AG owned approximately 0.36% of Sarepta Therapeutics worth $43,006,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in Sarepta Therapeutics in the 2nd quarter worth $31,000. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 175 shares during the period. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $43,000. Riggs Asset Managment Co. Inc. raised its stake in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the period. Finally, UMB Bank n.a. lifted its holdings in Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 197 shares in the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Price Performance

NASDAQ SRPT traded down $4.60 on Friday, hitting $133.34. The company had a trading volume of 777,554 shares, compared to its average volume of 1,375,611. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company's fifty day moving average price is $122.50 and its 200-day moving average price is $131.48. The company has a market capitalization of $12.74 billion, a PE ratio of 106.67 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 12-month low of $78.67 and a 12-month high of $173.25.

Analyst Ratings Changes

Several research firms have recently commented on SRPT. HC Wainwright initiated coverage on shares of Sarepta Therapeutics in a report on Monday, November 25th. They issued a "sell" rating and a $80.00 target price on the stock. UBS Group increased their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a report on Tuesday, September 17th. Royal Bank of Canada restated an "outperform" rating and set a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Raymond James reiterated an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Finally, Robert W. Baird lowered their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $175.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.